Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18360194 | 0.86 | KDM4E (0.46) | MEN1KMT2ALMNACA12CA1 | |
| SCHEMBL16114233 | 0.86 | GPR35 (0.44) | MEN1KMT2ARAB9ATHRBPDPK1 | |
| SCHEMBL12852739 | 0.83 | MEN1 (0.51) | MEN1KMT2ARAB9ATHRBPDPK1 | |
| SCHEMBL3937264 | 0.81 | LMNA (0.53) | MEN1KMT2ARAB9ATHRBPDPK1 | |
| SCHEMBL18773577 | 0.81 | CA12 (0.62) | MEN1KMT2ARAB9ATHRBPDPK1 | |
| SCHEMBL1424851 | 0.80 | HCAR3 (0.50) | MEN1KMT2ARAB9ALMNATP53 | |
| SCHEMBL18360121 | 0.79 | KDM4E (0.40) | MEN1KMT2ARAB9ALMNAHTT | |
| Hydrochloric Acid SCHEMBL1425016 | 0.78 | HCAR3 (0.49) | MEN1KMT2ARAB9ALMNATP53 | |
| SCHEMBL22999593 | 0.78 | HPGD (0.55) | MEN1KMT2ARAB9ATHRBPDPK1 | |
| SCHEMBL2526048 | 0.77 | MEN1 (0.46) | MEN1KMT2ARAB9ATHRBPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017004608-A1 | OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017004609-A1 | THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017004609-A1 | THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017004608-A1 | OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-8598208-B2 | Pyridine derivatives as S1P1/EDG1 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | S1PR5, S1PR1, S1PR2 | MEN1 394/4885KMT2A 3087/4885RAB9A 3321/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MEN1 1303/4885KMT2A 2397/4885RAB9A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.